260 related articles for article (PubMed ID: 22356350)
41. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations.
Daley-Yates PT; Baker RC
Br J Clin Pharmacol; 2001 Jan; 51(1):103-5. PubMed ID: 11167672
[TBL] [Abstract][Full Text] [Related]
42. MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children.
Berger W; Bousquet J; Fox AT; Just J; Muraro A; Nieto A; Valovirta E; Wickman M; Wahn U
Allergy; 2016 Aug; 71(8):1219-22. PubMed ID: 27043452
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetic characteristics and safety and tolerability of a reformulated azelastine hydrochloride nasal spray in patients with chronic rhinitis.
Berger WE
Expert Opin Drug Metab Toxicol; 2009 Jan; 5(1):91-102. PubMed ID: 19220164
[TBL] [Abstract][Full Text] [Related]
44. Quantification of fluticasone propionate in human plasma by LC-MS/MS and its application in the pharmacokinetic study of nasal spray at clinical doses.
Yamagata A; Adachi R; Yokokawa A; Furihata T; Shibasaki H
Drug Metab Pharmacokinet; 2024 Feb; 54():100541. PubMed ID: 38150944
[TBL] [Abstract][Full Text] [Related]
45. Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis.
Lieberman P; Kaliner MA; Wheeler WJ
Curr Med Res Opin; 2005 Apr; 21(4):611-8. PubMed ID: 15899111
[TBL] [Abstract][Full Text] [Related]
46. Two multicenter, randomized, single-blind, single-dose, crossover studies of specific sensory attributes of budesonide aqueous nasal spray and fluticasone propionate nasal spray.
Shah SR; Miller C; Pethick N; Uryniak T; Jones MK; O'Dowd L
Clin Ther; 2003 Aug; 25(8):2198-214. PubMed ID: 14512128
[TBL] [Abstract][Full Text] [Related]
47. A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol.
Messina JC; Offman E; Carothers JL; Mahmoud RA
Clin Ther; 2019 Nov; 41(11):2343-2356. PubMed ID: 31732149
[TBL] [Abstract][Full Text] [Related]
48. Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis.
Lieberman P; Meltzer EO; LaForce CF; Darter AL; Tort MJ
Allergy Asthma Proc; 2011; 32(2):151-8. PubMed ID: 21352639
[TBL] [Abstract][Full Text] [Related]
49. Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial.
LaForce C; Dockhorn RJ; Prenner BM; Chu TJ; Kraemer MJ; Widlitz MD; D'Eletto TA; Freitag JJ
Ann Allergy Asthma Immunol; 1996 Feb; 76(2):181-8. PubMed ID: 8595539
[TBL] [Abstract][Full Text] [Related]
50. Comparison of the effects of fluticasone propionate, aqueous nasal spray and levocabastine on inflammatory cells in nasal lavage and clinical activity during the pollen season in seasonal rhinitics.
Di Lorenzo G; Gervasi F; Drago A; Esposito Pellitteri M; Di Salvo A; Cosentino D; Potestio M; Colombo A; Candore G; Mansueto S; Caruso C
Clin Exp Allergy; 1999 Oct; 29(10):1367-77. PubMed ID: 10520057
[TBL] [Abstract][Full Text] [Related]
51. A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US.
Prenner BM
J Asthma Allergy; 2016; 9():135-43. PubMed ID: 27468241
[TBL] [Abstract][Full Text] [Related]
52. Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 microg in the treatment of seasonal allergic rhinitis.
Kaliner MA; Storms W; Tilles S; Spector S; Tan R; LaForce C; Lanier BQ; Chipps B
Allergy Asthma Proc; 2009; 30(3):255-62. PubMed ID: 19549426
[TBL] [Abstract][Full Text] [Related]
53. Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK.
Scadding G; Price D; El-Shanawany T; Ahmed S; Ray J; Sargur R; Kumar N
BMJ Open; 2017 Apr; 7(4):e014777. PubMed ID: 28442578
[TBL] [Abstract][Full Text] [Related]
54. Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers.
Roca-Ferrer J; Pujols L; Pérez-González M; Alobid I; Callejas B; Vicens-Artés S; Fuentes M; Valero A; Picado C; Castor D; Nguyen D; Mullol J
Allergy Asthma Clin Immunol; 2018; 14():86. PubMed ID: 30574167
[TBL] [Abstract][Full Text] [Related]
55. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays.
Daley-Yates PT; Kunka RL; Yin Y; Andrews SM; Callejas S; Ng C
Eur J Clin Pharmacol; 2004 Jun; 60(4):265-8. PubMed ID: 15114430
[TBL] [Abstract][Full Text] [Related]
56. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis.
Vargas R; Dockhorn RJ; Findlay SR; Korenblat PE; Field EA; Kral KM
J Allergy Clin Immunol; 1998 Aug; 102(2):191-7. PubMed ID: 9723660
[TBL] [Abstract][Full Text] [Related]
57. Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects.
Möllmann H; Wagner M; Krishnaswami S; Dimova H; Tang Y; Falcoz C; Daley-Yates PT; Krieg M; Stöckmann R; Barth J; Lawlor C; Möllmann AC; Derendorf H; Hochhaus G
J Clin Pharmacol; 2001 Dec; 41(12):1329-38. PubMed ID: 11762560
[TBL] [Abstract][Full Text] [Related]
58. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents.
Martin BG; Ratner PH; Hampel FC; Andrews CP; Toler T; Wu W; Faris MA; Philpot EE
Allergy Asthma Proc; 2007; 28(2):216-25. PubMed ID: 17479608
[TBL] [Abstract][Full Text] [Related]
59. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy.
Horak F; Zieglmayer UP; Zieglmayer R; Kavina A; Marschall K; Munzel U; Petzold U
Curr Med Res Opin; 2006 Jan; 22(1):151-7. PubMed ID: 16393441
[TBL] [Abstract][Full Text] [Related]
60. Fluticasone propionate: topical or systemic effects?
Howland WC
Clin Exp Allergy; 1996 May; 26 Suppl 3():18-22. PubMed ID: 8735854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
